Bellicum pharmaceuticals to participate in the b. riley securities 2022 virtual oncology conference

Houston, jan. 26, 2022 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq: blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that rick fair, president and ceo, will participate in the b. riley securities 2022 virtual oncology conference. a corporate presentation is scheduled for thursday, january 27, 2022 at 4 p.m. et / 1 p.m. pt.
BLCM Ratings Summary
BLCM Quant Ranking